Los Angeles Capital Management LLC Has $121,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Los Angeles Capital Management LLC grew its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACBGet Rating) by 24.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,471 shares of the biotechnology company’s stock after purchasing an additional 5,410 shares during the period. Los Angeles Capital Management LLC’s holdings in Pacific Biosciences of California were worth $121,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Versor Investments LP acquired a new stake in shares of Pacific Biosciences of California in the second quarter valued at approximately $44,000. Interchange Capital Partners LLC bought a new position in shares of Pacific Biosciences of California in the first quarter valued at $102,000. Integrity Advisory LLC bought a new position in shares of Pacific Biosciences of California in the first quarter valued at $103,000. Portland Investment Counsel Inc. bought a new position in shares of Pacific Biosciences of California in the first quarter valued at $109,000. Finally, Carret Asset Management LLC bought a new position in shares of Pacific Biosciences of California in the second quarter valued at $53,000.

Pacific Biosciences of California Stock Up 2.8 %

PACB stock opened at $10.30 on Monday. The company has a market cap of $2.33 billion, a PE ratio of -7.69 and a beta of 1.43. The business has a 50-day simple moving average of $6.84 and a 200 day simple moving average of $5.96. Pacific Biosciences of California, Inc. has a 52 week low of $3.85 and a 52 week high of $28.17. The company has a quick ratio of 11.07, a current ratio of 11.50 and a debt-to-equity ratio of 1.31.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PACB. Cowen decreased their target price on shares of Pacific Biosciences of California to $8.00 in a research note on Tuesday, August 9th. Piper Sandler decreased their target price on shares of Pacific Biosciences of California from $7.50 to $6.00 in a research note on Sunday, August 21st. Finally, Canaccord Genuity Group decreased their target price on shares of Pacific Biosciences of California from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Pacific Biosciences of California presently has a consensus rating of “Hold” and a consensus price target of $17.40.

Insider Activity at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Susan G. Kim sold 12,968 shares of the business’s stock in a transaction dated Thursday, September 29th. The stock was sold at an average price of $5.61, for a total transaction of $72,750.48. Following the completion of the transaction, the insider now owns 163,488 shares of the company’s stock, valued at $917,167.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Pacific Biosciences of California news, insider Christian O. Henry sold 91,307 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $5.78, for a total transaction of $527,754.46. Following the completion of the transaction, the insider now owns 688,551 shares of the company’s stock, valued at $3,979,824.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Susan G. Kim sold 12,968 shares of the business’s stock in a transaction dated Thursday, September 29th. The stock was sold at an average price of $5.61, for a total value of $72,750.48. Following the transaction, the insider now directly owns 163,488 shares of the company’s stock, valued at approximately $917,167.68. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.

Pacific Biosciences of California Profile

(Get Rating)

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.

Featured Articles

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.